A new database for studying repetitive DNA in cancer
Researchers analyzed over 7,000 samples to see how transposable elements change during cancer treatment.
A new resource called the Transposable Element Differential Expression Database, or TEDEdb, has been created. It explores how repetitive DNA sequences behave in cancer.
The study involved a uniform reanalysis of over 7,000 RNA-seq samples. This included more than 2,000 differential expression experiments. These covered 220 cancer cell lines and 700 drug treatments.
The human genome contains nearly 50% repetitive DNA. These sequences are often called junk DNA. Transposable elements, or TEs, are a type of these sequences. TEs can induce innate immune responses when they are derepressed following treatment with epigenetic therapies.
The researchers found that TE expression is more prone to batch effects than gene expression alone. This required using meta-analysis techniques to find global trends. They confirmed that DNMTi and HDACis are powerful inducers of TE expression.
Non-epigenetic compounds like cyclin-dependent kinase and topoisomerase inhibitors also induce robust up-regulation of TE-derived repetitive DNA elements. This induction is consistent with transcriptional signatures of viral mimicry response.
Epigenetic therapy has been suggested to augment cancer therapies. TEs are traditionally ignored in most RNA-seq studies. Their expression is often excluded from publicly available data sources.
Key facts
- The TEDEdb includes data from over 7,000 RNA-seq samples.
- TE expression can be induced by DNMTi and HDACis.
- Cyclin-dependent kinase and topoisomerase inhibitors also induce TE-derived repetitive DNA elements.